Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen
Seiji Kawamoto, … , Craig Gerard, Raif S. Geha
Seiji Kawamoto, … , Craig Gerard, Raif S. Geha
Published August 1, 2004
Citation Information: J Clin Invest. 2004;114(3):399-407. https://doi.org/10.1172/JCI19082.
View: Text | PDF
Article Immunology

The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen

  • Text
  • PDF
Abstract

Mechanical injury to the skin results in activation of the complement component C3 and release of the anaphylatoxin C3a. C3a binds to a seven-transmembrane G protein–coupled receptor, C3aR. We used C3aR–/– mice to examine the role of C3a in a mouse model of allergic inflammation induced by epicutaneous sensitization with OVA. C3aR–/– mice exhibited an exaggerated Th2 response to epicutaneous but not to intraperitoneal sensitization with OVA, as evidenced by significantly elevated levels of serum OVA-specific IgG1 and significantly increased secretion of the Th2 cytokines IL-4, IL-5, and IL-10 by antigen-stimulated splenocytes. Presentation of OVA peptide by C3aR–/– APCs caused significantly more IL-4 and IL-5 secretion by T cells from OVA–T cell receptor (OVA-TCR) transgenic mice compared with presentation by WT APCs. C3a inhibited the ability of splenocytes, but not of highly purified T cells, to secrete Th2 cytokines in response to TCR ligation. This inhibition was mediated by IL-12 secreted by APCs in response to C3a. These results suggest that C3a-C3aR interactions inhibit the ability of APCs to drive Th2 cell differentiation in response to epicutaneously introduced antigen and may have important implications for allergic skin diseases.

Authors

Seiji Kawamoto, Ali Yalcindag, Dhafer Laouini, Scott Brodeur, Paul Bryce, Bao Lu, Alison A. Humbles, Hans Oettgen, Craig Gerard, Raif S. Geha

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
(A) Effect of pretreatment of BALB/C splenic DCs with C3a on their abili...
(A) Effect of pretreatment of BALB/C splenic DCs with C3a on their ability to support cytokine production by DO11.10 TCR-OVA transgenic T cells in response to OVA peptide. (B) Effect of supernatants of splenic DCs treated with C3a, then depleted of C3a, on cytokine production by DO11.10 TCR-OVA transgenic T cells in response to OVA peptide presented by fresh DCs. Columns and error bars represent mean ± SEM of three experiments. *P < 0.05. (C) Dose-response analysis of the effect of supernatants from C3a-stimulated DCs on IL-4 secretion. Sup, supernatant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts